Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company engaged in active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) products.
On the financial front, the company’s consolidated net profit rose 1.8% to Rs 1,418.10 crore on an 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25.
The scrip rose 1% to end at Rs 1,316.40 on the BSE on Friday, 12 September 2025.
Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services, including APIs, generics, branded generics, biosimilars, and OTC.
The company’s consolidated net profit rose 1.8% to Rs 1,418.10 crore on an 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25.
Shares of Dr Reddys Laboratories shed 0.04% to Rs 1,268 on the BSE.